Tiffany Yeh1, Michele Yeung1, Eric J Sherman2, R Michael Tuttle1, Mona M Sabra1. 1. Endocrinology Service, Memorial Sloan Kettering Cancer Center, Weill-Cornell College of Medicine, New York, New York, USA. 2. Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill-Cornell College of Medicine, New York, New York, USA.
Abstract
Purpose: To evaluate the impact of structural disease progression of metastatic lesions after initial surgery on overall survival (OS) of patients presenting with metastatic medullary thyroid cancer (MTC). We used tumor volume doubling time (TVDT) as a marker of structural disease progression and aimed to correlate the average structural tumor volume doubling time (midDT) with OS in MTC patients after initial surgery. Methods: In this retrospective study, we examined the clinical characteristics; average tumor volume doubling times of neck, lung, and liver metastasis; and disease-specific survival of patients with metastatic MTC. Results: Tumor growth is constant in MTC metastasis, irrespective of location of the metastasis. The median correlation coefficient (r) and the coefficient of determination (r2) were similar in lung metastasis (r = 0.91, r2 = 0.95) and liver metastasis (r = 0.88, r2 = 0.94), and comparable in neck metastasis (r = 0.73, r2 = 0.85). Patients with metastatic MTC with a midDT ≤1 year have a worse prognosis than those with higher midDT (p = 0.002). Those with midDT ≤1 year had a median OS of 11.1 years [confidence interval (CI) 7.4-14.8 years]. In contrast, patients with midDT 1-3 years had a median OS of 16.5 years [CI 10.3-22.6 years]. All patients with midDT ≥3 survived by the end of the follow-up period. Preliminary results suggest that measurement of midDT can predict response to molecular targeted therapies. Conclusions: In conclusion, TVDT is a strong predictor of OS in patients with recurrent or metastatic MTC, can be used as a marker of progression, and potentially can help select patients who may benefit from molecular targeted therapy.
Purpose: To evaluate the impact of structural disease progression of metastatic lesions after initial surgery on overall survival (OS) of patients presenting with metastatic medullary thyroid cancer (MTC). We used tumor volume doubling time (TVDT) as a marker of structural disease progression and aimed to correlate the average structural tumor volume doubling time (midDT) with OS in MTC patients after initial surgery. Methods: In this retrospective study, we examined the clinical characteristics; average tumor volume doubling times of neck, lung, and liver metastasis; and disease-specific survival of patients with metastatic MTC. Results:Tumor growth is constant in MTC metastasis, irrespective of location of the metastasis. The median correlation coefficient (r) and the coefficient of determination (r2) were similar in lung metastasis (r = 0.91, r2 = 0.95) and liver metastasis (r = 0.88, r2 = 0.94), and comparable in neck metastasis (r = 0.73, r2 = 0.85). Patients with metastatic MTC with a midDT ≤1 year have a worse prognosis than those with higher midDT (p = 0.002). Those with midDT ≤1 year had a median OS of 11.1 years [confidence interval (CI) 7.4-14.8 years]. In contrast, patients with midDT 1-3 years had a median OS of 16.5 years [CI 10.3-22.6 years]. All patients with midDT ≥3 survived by the end of the follow-up period. Preliminary results suggest that measurement of midDT can predict response to molecular targeted therapies. Conclusions: In conclusion, TVDT is a strong predictor of OS in patients with recurrent or metastatic MTC, can be used as a marker of progression, and potentially can help select patients who may benefit from molecular targeted therapy.
Entities:
Keywords:
medullary thyroid cancer; metastasis; tumor volume doubling time
Authors: Johannes A A Meijer; Saskia le Cessie; Wilbert B van den Hout; Job Kievit; Johannes W Schoones; Johannes A Romijn; Johannes W A Smit Journal: Clin Endocrinol (Oxf) Date: 2009-06-26 Impact factor: 3.478
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: R Michael Tuttle; Marcia S Brose; Enrique Grande; Sun Wook Kim; Makoto Tahara; Mona M Sabra Journal: Best Pract Res Clin Endocrinol Metab Date: 2017-05-12 Impact factor: 4.690
Authors: G Hajje; I Borget; S Leboulleux; C Chougnet; A Al Ghuzlan; H Mirghani; C Caramella; D Hartl; M Schlumberger; E Baudin Journal: Eur J Endocrinol Date: 2012-12-31 Impact factor: 6.664
Authors: Anne Laure Giraudet; Abir Al Ghulzan; Anne Aupérin; Sophie Leboulleux; Ahmed Chehboun; Frédéric Troalen; Clarisse Dromain; Jean Lumbroso; Eric Baudin; Martin Schlumberger Journal: Eur J Endocrinol Date: 2008-02 Impact factor: 6.664